After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it ...

Chen, D. and Li, L. (2025) Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB-IMRT: A ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...